Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6218758 | 0.84 | KDM4E (0.40) | KDM4EALDH1A1TSHRSLC6A3PKM | |
| Hydrochloric Acid SCHEMBL6243419 | 0.83 | KDM4E (0.39) | KDM4EALDH1A1TSHRPKMHRH1 | |
| SCHEMBL7378461 | 0.79 | KDM4E (0.35) | KDM4EPKM | |
| SCHEMBL2522189 | 0.77 | KDM4E (0.38) | KDM4EALDH1A1TSHRPKMHRH1 | |
| SCHEMBL17001553 | 0.76 | — | — | |
| SCHEMBL20899840 | 0.72 | ALDH1A1 (0.32) | KDM4EALDH1A1TSHRHRH1KCNH2 | |
| SCHEMBL3842916 | 0.71 | KDM4E (0.34) | KDM4EALDH1A1TSHR | |
| SCHEMBL907621 | 0.71 | KDM4E (0.44) | KDM4EALDH1A1TSHRPKMHRH1 | |
| SCHEMBL11983474 | 0.71 | KDM4E (0.39) | KDM4EALDH1A1TSHRPKMHRH1 | |
| SCHEMBL16313108 | 0.71 | ALDH1A1 (0.37) | ALDH1A1TSHRHRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | disclosed |
| EP-2099754-A1 | ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008073929-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267697-A1 | ION CHANNEL MODULATORS | CACNA1E, CACNA1A, CACNA1S | KDM4E 1978/4885ALDH1A1 957/4885TSHR 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.